Rohto PharmaceuticalLtd Management
Management criteria checks 3/4
Rohto PharmaceuticalLtd's CEO is Yamada Kunio, appointed in Jun 2009, has a tenure of 15.5 years. total yearly compensation is ¥212.00M, comprised of 89.6% salary and 10.4% bonuses, including company stock and options. directly owns 1.74% of the company’s shares, worth ¥10.66B. The average tenure of the management team and the board of directors is 2.8 years and 5.5 years respectively.
Key information
Yamada Kunio
Chief executive officer
JP¥212.0m
Total compensation
| CEO salary percentage | 89.6% |
| CEO tenure | 15.5yrs |
| CEO ownership | 1.7% |
| Management average tenure | 2.8yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Rohto PharmaceuticalLtd's (TSE:4527) Upcoming Dividend Will Be Larger Than Last Year's
Dec 06
Rohto Pharmaceutical Co.,Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 15Rohto Pharmaceutical Co.,Ltd. (TSE:4527) Shares Could Be 25% Below Their Intrinsic Value Estimate
Nov 07These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Reasonably Well
Oct 20Shareholders Should Be Pleased With Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Price
Oct 06Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down
Sep 22Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors
Aug 25Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next
Aug 11Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?
Jul 11Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)
Jun 23Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares
Jun 10Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward
May 14These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely
Apr 03Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching
Mar 21Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year
Mar 07Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)
Feb 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | JP¥27b |
| Jun 30 2024 | n/a | n/a | JP¥30b |
| Mar 31 2024 | JP¥212m | JP¥190m | JP¥31b |
| Dec 31 2023 | n/a | n/a | JP¥31b |
| Sep 30 2023 | n/a | n/a | JP¥30b |
| Jun 30 2023 | n/a | n/a | JP¥28b |
| Mar 31 2023 | JP¥205m | JP¥183m | JP¥26b |
| Dec 31 2022 | n/a | n/a | JP¥26b |
| Sep 30 2022 | n/a | n/a | JP¥23b |
| Jun 30 2022 | n/a | n/a | JP¥23b |
| Mar 31 2022 | JP¥196m | JP¥178m | JP¥21b |
| Dec 31 2021 | n/a | n/a | JP¥23b |
| Sep 30 2021 | n/a | n/a | JP¥21b |
| Jun 30 2021 | n/a | n/a | JP¥20b |
| Mar 31 2021 | JP¥185m | JP¥176m | JP¥17b |
| Dec 31 2020 | n/a | n/a | JP¥14b |
| Sep 30 2020 | n/a | n/a | JP¥14b |
| Jun 30 2020 | n/a | n/a | JP¥15b |
| Mar 31 2020 | JP¥192m | JP¥179m | JP¥15b |
| Dec 31 2019 | n/a | n/a | JP¥11b |
| Sep 30 2019 | n/a | n/a | JP¥10b |
| Jun 30 2019 | n/a | n/a | JP¥9b |
| Mar 31 2019 | JP¥181m | JP¥173m | JP¥10b |
Compensation vs Market: Yamada's total compensation ($USD1.38M) is above average for companies of similar size in the JP market ($USD912.83K).
Compensation vs Earnings: Yamada's compensation has been consistent with company performance over the past year.
CEO
Yamada Kunio (68 yo)
15.5yrs
Tenure
JP¥212,000,000
Compensation
Mr. Yamada Kunio had been the President at Rohto Pharmaceutical Co. Ltd. since June 9, 2009 until 2019. Mr. Kunio has been the Chairman of the Board of Directors and Representative Director at Rohto Pharma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 15.5yrs | JP¥212.00m | 1.74% ¥ 10.7b | |
| President | 5.5yrs | no data | 0.0075% ¥ 45.5m | |
| EVP, CFO & Director | 2.8yrs | no data | 0.021% ¥ 125.8m | |
| EVP, CTO & Director | 2.8yrs | no data | 0.018% ¥ 109.8m | |
| Senior Executive Officer and General Manager of Marketing Division | no data | no data | 0.0053% ¥ 32.1m | |
| CHRO & Director | 1.5yrs | no data | no data | |
| MD, Chief Strategy Officer & Director | 2.8yrs | no data | 0.0039% ¥ 24.1m |
2.8yrs
Average Tenure
63.5yo
Average Age
Experienced Management: 4527's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 25.5yrs | JP¥212.00m | 1.74% ¥ 10.7b | |
| President | 5.5yrs | no data | 0.0075% ¥ 45.5m | |
| EVP, CFO & Director | 13.5yrs | no data | 0.021% ¥ 125.8m | |
| EVP, CTO & Director | 14.5yrs | no data | 0.018% ¥ 109.8m | |
| CHRO & Director | 1.5yrs | no data | no data | |
| MD, Chief Strategy Officer & Director | 6.5yrs | no data | 0.0039% ¥ 24.1m | |
| Standing Corporate Auditor | 8.5yrs | no data | 0.027% ¥ 163.3m | |
| Independent Outside Director | 5.5yrs | no data | no data | |
| Independent Outside Director | 4.5yrs | no data | no data | |
| Independent Outside Director | 2.5yrs | no data | 0.00044% ¥ 2.7m | |
| Independent Outside director | 2.5yrs | no data | no data | |
| Independent Outside Director | less than a year | no data | no data |
5.5yrs
Average Tenure
62.5yo
Average Age
Experienced Board: 4527's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 23:25 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rohto Pharmaceutical Co.,Ltd. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitsuko Miyasako | Barclays |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |
| Hidemaru Yamaguchi | Citigroup Inc |